Stockscreener 앱 받기
1.13
0.88%
-0.01
시장 영업 전:
1.12
-0.010
-0.88%
Bioxcel Therapeutics Inc 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria
BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock - Investing.com India
BioXcel CFO Richard Steinhart sells $7,426 of stock - Investing.com UK
BioXcel Therapeutics chief legal officer sells $7,111 in stock - Investing.com
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock - Investing.com
BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment - Stock Titan
BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes - Stock Titan
BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes - Stock Titan
BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan
BioXcel Shareholder Notice - TMX Newsfile
BTAI Should I Buy - Intellectia AI
BioXcel Therapeutics (BTAI) Form 144: 19,419 RSUs vested, 30.9M shares outstanding - Stock Titan
BioXcel Therapeutics (NASDAQ: BTAI) notice to sell 6,560 vested restricted shares - Stock Titan
BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan
[144] BioXcel Therapeutics, Inc. SEC Filing - Stock Titan
Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026? EPS Not - GuruFocus
BioXcel Therapeutics, Inc. (BTAI) reports Q1 loss, lags revenue estimates - MSN
Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026 Results? - GuruFocus
BioXcel Therapeutics (BTAI) Reports First Quarter Revenue and Re - GuruFocus
BioXcel Therapeutics 1Q Loss $12.7M >BTAI - Moomoo
Press Release: BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
BioXcel Therapeutics Reports Q1 2026 Results, FDA Accepts IGALMI sNDA for At-Home Use, and Explores Strategic Options - Minichart
Armistice Capital reports 7.05% stake in BioXcel (NASDAQ: BTAI) - Stock Titan
BioXcel weighs sale, other strategic options as New Haven biotech continues losses - Hartford Business Journal
BTAI Financials: Income Statement, Balance Sheet & Cash Flow | Bioxcel Therapeutics Inc - Stock Titan
BioXcel Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
BioXcel Therapeut reports Q1 2026 net loss $12.7M, revenue $0.2M; FDA sets IGALMI at-home PDUFA Nov 14, 2026 - TradingView
BioXcel Therapeutics 1Q 2026: Revenue $206K, Net income ($12.69M), EPS ($0.54) — 10-Q Summary - TradingView
BioXcel Therapeutics (NASDAQ: BTAI) posts Q1 2026 loss, limited cash and going concern risk - Stock Titan
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioXcel Therapeutics (BTAI) posts Q1 2026 loss amid going concern risk - Stock Titan
BioXcel at-home agitation drug gets Nov. 14, 2026 FDA action date - Stock Titan
Number of shareholders of BioXcel Therapeutics, Inc. – SWB:BX20 - TradingView
AI For Pharma And Biotech Market Is Going to Boom | BioXcel Therapeutics, BenevolentAI, NVIDIA Corporation - openPR.com
BioXcel Therapeutics, Inc. (BTAI) Latest Stock News & Headlines - Yahoo Finance
BioXcel Therapeutics (BTAI) CEO exercises 18,000 RSUs, updates share holdings - Stock Titan
BioXcel Therapeutics (BTAI) CFO converts 9,000 RSUs, now holds 15,645 shares - Stock Titan
BioXcel (NASDAQ: BTAI) CSO converts 9,000 RSUs to stock - Stock Titan
Javier Rodriguez of BioXcel (NASDAQ: BTAI) converts 9,000 RSUs to shares - Stock Titan
BioXcel Deadline Alert - TMX Newsfile
BioXcel Therapeutics, Inc. (BTAI) expected to beat earnings estimates: Should you buy? - MSN
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
BioXcel Shareholder Action Reminder - TMX Newsfile
1.92%
4.44%
자본화:
|
볼륨(24시간):